- Spectrum Pharmaceuticals' (NASDAQ:SPPI) Allos Therapeutics and Fresenius Kabi USA have entered into settlement agreement to resolve their patent litigation relating to Folotyn (pralatrexate injection). Under the terms of the settlement, Fresenius will be permitted to market a generic version of Folotyn in the U.S. on November 15, 2022 or earlier under certain circumstances.
- The Company has also settled with Teva Pharmaceuticals USA (NYSE:TEVA), Dr. Reddy’s Laboratories (NYSE:RDY) and Sandoz (NYSE:NVS).